Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Anavex Life Sciences (Nasdaq: AVXL), a clinical-stage biopharmaceutical company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Thursday, January 16th, 2025, at the Westin St. Francis in San Francisco, CA, from 9:00 AM to 9:40 AM Pacific Time.
The company, which focuses on developing innovative treatments for neurological conditions including Alzheimer's disease, Parkinson's disease, schizophrenia, and Rett syndrome, will be represented by Christopher U Missling, PhD, President & Chief Executive Officer. The presentation will be accessible via audio webcast through the Investors section of Anavex's website, with a replay available later that day.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AVXL gained 6.15%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th 2025, at the Westin St. Francis in San Francisco, CA. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled 09:00 AM – 09:40 AM (Pacific Time).
An audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com. A replay of the session will be available later that day.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When is Anavex Life Sciences (AVXL) presenting at the J.P. Morgan Healthcare Conference 2025?
How can investors access AVXL's J.P. Morgan Healthcare Conference presentation?
What therapeutic areas does AVXL focus on according to the announcement?
Who will be presenting for AVXL at the 2025 J.P. Morgan Healthcare Conference?
